Oprelvekin

Also known as: AGIF, adipogenesis inhibitory factor, interleukin inhibitory precursor

Drug #2303

Interleukin eleven (IL-11) is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. IL-11 is a member of a family of human growth factors which includes human growth hormone, granulocyte colonystimulating factor (G-CSF), and other growth factors. Oprelvekin, is produced in Escherichia coli (E. coli) by recombinant DNA technology. oprelveki is polypeptide with 177 amino acids in length and differs from the 178 amino acid length of native IL-11 only in lacking the amino-terminal proline residue. This alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo.

← Previous drug Next drug →

Primary Characteristics

Oprelvekin is also known as AGIF, adipogenesis inhibitory factor, interleukin inhibitory precursor.

It is of Synthetic origin and belongs to non-glycosylate.

Non-proprietary name: Oprelvekin.

Pharmacokinetics

Absorption: Oprelvekin has an oral bioavailability is 80%.

Elimination: plasma half-life is 6.9 ± 1.7 hrs., renal excretion is by urine.

Indications

Oprelvekin is primarily indicated in conditions like Thrombocytopenia.

Contraindications

None recorded.

Dosage

Oprelvekin's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
25 mcg/Kg	25 mcg/Kg	—	SC	with severe renal impairment. Dosing should be initiated six to 24 hours after the completion of chemotherapy
50 mcg/Kg	50 mcg/Kg	—	SC	without severe renal impairment. Dosing should be initiated six to 24 hours after the completion of chemotherapy
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Oprelvekin in overdosage may give rise to further complications which include Fever , Atrial fibrillation , Syncope , Pneumonia, neutropenic fever.

Oprelvekin is known to cause more or less tolerable side effects which are usually transient. These include atrial arrhythmia, Conjunctival irritation, Dypnoea, Edema, Palpitation, pleural effusion, Tachycardia.

Warnings / Precautions

Allergic Reactions Including Anaphylaxis, Increased Toxicity Following Myeloablative Therapy, fluid retention, Dilutional Anemia, arrhythmias and pulmonary edema,Papilledema, Patients with a history of stroke or transient ischemic attack may also be at increased risk

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

1.5 mg 3 mg

Storage Conditions

Oprelvekin should be stored injection.

Drug Classification

1.8.1 — Immunomodulators

Manufacturers

Manufacturers of Oprelvekin in Pakistan:

Medinet